Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA grants GSK’s Benlysta orphan drug designation for systemic sclerosis

By Brian Buntz | February 1, 2023

GSKGSK (NYSE:GSK) announced that FDA has granted Orphan Drug Designation (ODD) to Benlysta (belimumab) for systemic sclerosis (SSc), a rare autoimmune disease that can affect multiple organs.

Interstitial lung disease (ILD) is the leading cause of death in SSc patients.

The monoclonal antibody Benlysta is a B-lymphocyte stimulator (BLyS) specific inhibitor that binds to soluble BLyS. A soluble ligand belonging to the TNF cytokine family, BLyS is elevated in patients with systemic autoimmune diseases such as systemic lupus erythematosus and lupus nephritis. Blocking BLyS decreases the number of abnormal B cells, supporting a reduction in the severity of autoimmune diseases.

GSK shares held steady after announcing the news and Q4 results, dipping 0.20% to $35.19 in mid-day trading.

The company intends to launch a Phase 2/3 study of belimumab for SSc-associated ILD in the first half of 2023.

Benlysta could address an unmet need in systemic sclerosis

With limited options for SSc-ILD, this orphan drug designation highlights the need for further research into belimumab’s potential to address an unmet need for SSc patients, GSK said. The company is committed to exploring how belimumab can help with B-cell-driven autoimmune diseases.

FDA’s orphan drug designation program is limited to potential new therapies for rare diseases affecting fewer than 200,000 people in the U.S.

FDA first approved Benlysta in 2011 for lupus. In 2019, the drug won an indication for intravenous use in children at least five years old with lupus. Belimumab has also won indications for adults and children with active lupus nephritis.

Last February, China’s National Medical Products Administration (NMPA) approved Benlysta for adults with active lupus nephritis (LN), a type of kidney disease affecting many lupus patients.

GSK announced upbeat financials

GSK also announced Q4 earnings that beat the Wall Street consensus, thanks partly to solid vaccine demand.

The company anticipates that operating profit, excluding some expenses, could increase by up to 12% in 2023. The guidance was also higher than what analysts had expected.

GSK’s CEO Emma Walmsley has sharpened the company’s focus on innovative drugs and vaccines while also working to reinvigorate its pipeline.

 


Filed Under: Immunology
Tagged With: Benlysta
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

NBC 2025 Preview: Inside CheckImmune’s playbook for cell-specific drug insights
Proscia raises $50M for AI-driven pathology
Rosnilimab phase 2b trial shows promise in treating RA
African american male scientist analyzing a specimen in a laboratory setting, portraying research and healthcare.
5 trends on display at JPM 2025: Deals, data, and the future of precision medicine
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE